Bionovo, a pharmaceutical company, has hired David Boyle as senior vice president (SVP) and chief financial officer (CFO). He will be responsible for directing Bionovo’s financial strategy, accounting, financial planning, business development and investor relations functions. Thomas Chesterman, the company’s former CFO, is to pursue other business interests.
Boyle brings extensive operational and international financial experience to Bionovo. He was previously SVP and CFO of AVI BioPharma, a Washington-based company developing RNA-based therapeutics. Prior to AVI, he was vice president, finance and CFO of XOMA, a California-based leader in the discovery and development of therapeutic antibodies. In addition to his past positions as vice president of finance at Polycom and director of business development at Intel, Boyle has held senior positions in biotechnology and specialty pharmaceutical companies. He was previously at Salix Pharmaceuticals in the US and at Ares Serono Group, both in the US and Switzerland.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.